{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:46:24Z","timestamp":1770511584402,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,7,12]],"date-time":"2011-07-12T00:00:00Z","timestamp":1310428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:p>A. Nihtinen, V.\u2010J. Anttila, T. Ruutu, E. Juvonen, L. Volin. Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis.\u2028Transpl Infect Dis 2011. All rights reserved<\/jats:p><jats:p>\n            <jats:bold>Abstract: <\/jats:bold> In this retrospective study we evaluated the impact of amphotericin B (AmB) deoxycholate inhalation prophylaxis on invasive aspergillosis (IA) in 611 allogeneic stem cell transplant (alloSCT) recipients and their tolerance of the inhalations. The inhalations were not used in 1996\u20132000 (Period I). In 2001\u20132005 (Period II) all patients with acute graft\u2010versus\u2010host disease treated with high\u2010dose methylprednisolone used the inhalation prophylaxis with a dose of 25\u2003mg daily. No systemic antifungal prophylaxis was routinely used during the study period. IA was detected in 17 (13 proven, 4 probable) out of 257 (6.6%) patients transplanted in Period I and in 9 (6 proven, 3 probable) out of 354 (2.5%) patients transplanted in Period II (<jats:italic>P<\/jats:italic>=0.007). The median time to the diagnosis of IA was 95 days and 155 days post transplant in the 2 periods (<jats:italic>P<\/jats:italic>=0.225). The mortality of the patients with IA was 94.1% and 66.6% in Period I and Period II. The median duration of AmB inhalation prophylaxis was 84 days. Breakthrough IA was detected in 1 of the 111 (1%) patients during the prophylaxis. No discontinuation of prophylaxis due to side effects was recorded. Overall, with a median follow\u2010up of 3.5 and 4.6 years, 42.4% and 59% of the patients were alive in Period I and Period II, respectively (<jats:italic>P<\/jats:italic>=0.001). In conclusion, the incidence of IA fell during the AmB inhalation prophylaxis, and the inhalations were well tolerated. Mortality of patients with IA was high. The overall survival of patients was significantly higher in Period II, indicating the advances made in SCT therapy over the 10\u2010year period.<\/jats:p>","DOI":"10.1111\/j.1399-3062.2011.00661.x","type":"journal-article","created":{"date-parts":[[2011,7,12]],"date-time":"2011-07-12T14:01:41Z","timestamp":1310479301000},"page":"24-32","source":"Crossref","is-referenced-by-count":16,"title":["Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis"],"prefix":"10.1111","volume":"14","author":[{"given":"A.","family":"Nihtinen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.\u2010J.","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ruutu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Juvonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Volin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/516480"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/339202"},{"key":"e_1_2_6_4_2","first-page":"1041","article-title":"Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients","volume":"47","author":"Garcia\u2010Vidal C","year":"2008","journal-title":"biological risk factors for infections according to time after transplantation"},{"key":"e_1_2_6_5_2","first-page":"1091","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006","volume":"50","author":"Kontoyiannis DP","year":"2010","journal-title":"overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database"},{"key":"e_1_2_6_6_2","first-page":"475","article-title":"Invasive fungal infections after allogeneic peripheral blood stem cell transplantation","volume":"116","author":"Martino R","year":"2002","journal-title":"incidence and risk factors in 395 patients"},{"key":"e_1_2_6_7_2","first-page":"181","article-title":"Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia","volume":"159","author":"Shaukat A","year":"2005","journal-title":"clinical, radiologic, and pathologic characteristics"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700737"},{"key":"e_1_2_6_9_2","first-page":"361","article-title":"Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors","volume":"44","author":"Mikulska M","year":"2009","journal-title":"an analysis of 306 patients"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft\u2010versus\u2010host disease","volume":"356","author":"Ullman AJ","year":"2007","journal-title":"N Engl J Med"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(96)00363-6"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2003.09.028"},{"key":"e_1_2_6_13_2","first-page":"121","article-title":"Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation","volume":"9","author":"Lowry CM","year":"2007","journal-title":"a retrospective study"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01695915"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2006.00125.x"},{"key":"e_1_2_6_16_2","first-page":"132","article-title":"Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT","volume":"46","author":"Morello E","year":"2011","journal-title":"a single-center retrospective study"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000101516.08327.A9"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702604"},{"key":"e_1_2_6_19_2","first-page":"333","article-title":"Invasive Aspergillus infections in allo\u2010SCT recipients","volume":"45","author":"Nihtinen A","year":"2010","journal-title":"environmental sampling, nasal and oral colonization and galactomannan testing"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_6_21_2","first-page":"4358","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients","volume":"100","author":"Marr KA","year":"2002","journal-title":"changes in epidemiology and risk factors"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/344906"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.06.003"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.11.014"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm463"},{"issue":"1","key":"e_1_2_6_26_2","first-page":"S49","article-title":"Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation","volume":"43","author":"Morgan J","year":"2005","journal-title":"interim results of a prospective multicenter surveillance program"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/522189"},{"key":"e_1_2_6_28_2","first-page":"3654","article-title":"Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia","volume":"93","author":"Schwartz S","year":"1999","journal-title":"results of a prospective randomized multicenter trial"},{"key":"e_1_2_6_29_2","first-page":"1401","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia","volume":"46","author":"Rijnders BJ","year":"2008","journal-title":"a randomized, placebo-controlled trial"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199302000-00011"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.3.750"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01726364"},{"key":"e_1_2_6_33_2","first-page":"403","article-title":"Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients","volume":"5","author":"Conneally E","year":"1990","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3062.2011.00661.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3062.2011.00661.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:42:25Z","timestamp":1698640945000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3062.2011.00661.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1399-3062.2011.00661.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3062.2011.00661.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,12]]}}}